700053P
Avanti
25-hydroxycholesterol-d6
Avanti Polar Lipids
Sinonimo/i:
26,26,26,27,27,27-hexadeuterocholest-5-ene-3β,25-diol; 25-hydroxycholest-5-en-3-ol(d6)
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Formula empirica (notazione di Hill):
C27H40D6O2
Numero CAS:
Peso molecolare:
408.69
Codice UNSPSC:
41141804
NACRES:
NA.25
Prodotti consigliati
Descrizione
cholest-5-ene-3β,25-diol-d6
Saggio
>99% (TLC)
Forma fisica
powder
Confezionamento
pkg of 1 × 1 mg (700053P-1mg)
Produttore/marchio commerciale
Avanti Polar Lipids
Condizioni di spedizione
dry ice
Temperatura di conservazione
−20°C
Categorie correlate
Descrizione generale
25-hydroxycholesterol (25HC) is synthesized from cholesterol in the presence of oxygen and enzyme cholesterol 25-hydroxylase and the conversion is dependent on nicotinamide adenine dinucleotide phosphate (NADPH) during toll-like receptor activation. 25HC is catabolized to 7α-hydroxylated sterol. 25-hydroxycholesterol-d6 is the deuterated form of 25-hydroxycholesterol.
Applicazioni
25-hydroxycholesterol-d6 has been used as an internal standard:
- in the quantification of 25-OHC in jejunum samples by liquid chromatography with tandem mass spectrometry (LC-MS-MS)
- in plasma samples by liquid chromatography-mass spectrometry analysis
- for calibration curve generation for plasma oxysterol quantification
Azioni biochim/fisiol
25-hydroxycholesterol is a liver X receptor ligand. This bioactive lipid regulates immune response and macrophages production from monocytes. 25-HC serves as an antiviral effector and may have therapeutic potential. It reduces cholesterol biosynthesis by inactivating sterol regulatory element binding protein and inhibits HMG-CoA reductase (HMGCR). 25-HC may play a protective role in myocardial ischemia-reperfusion injury by inhibiting apoptosis and regulating mitogen-activated protein kinase (MAPK) pathway.
Confezionamento
5 mL Amber Glass Screw Cap Vial (700053P-1mg)
Note legali
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Codice della classe di stoccaggio
11 - Combustible Solids
Punto d’infiammabilità (°F)
No data available
Punto d’infiammabilità (°C)
No data available
Certificati d'analisi (COA)
Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
I clienti hanno visto anche
Editorial: 25-Hydroxycholesterol: a new life in immunology.
Jeffrey G McDonald et al.
Journal of leukocyte biology, 88(6), 1071-1072 (2010-12-03)
Ying Liu et al.
Journal of lipid research, 59(3), 439-451 (2018-01-05)
Cholesterol 25-hydroxylase (CH25H) catalyzes the production of 25-hydroxycholesterol (25-HC), an oxysterol that can play an important role in different biological processes. However, the mechanisms regulating CH25H expression have not been fully elucidated. In this study, we determined that CH25H is
Pallavi Mukherjee et al.
Journal of lipid research, 58(8), 1636-1647 (2017-06-09)
Feeding LDL receptor (LDLR)-null mice a Western diet (WD) increased the expression of IFN-β in jejunum as determined by quantitative RT-PCR (RT-qPCR), immunohistochemistry (IHC), and ELISA (all P < 0.0001). WD also increased the expression of cholesterol 25-hydroxylase (CH25H) as
Plasma oxysterol levels in luminal subtype breast cancer patients are associated with clinical data.
Alzbeta Kloudova-Spalenkova et al.
The Journal of steroid biochemistry and molecular biology, 197, 105566-105566 (2019-12-25)
Oxygenated metabolites of cholesterol (oxysterols) have been previously demonstrated to contribute to progression of various cancers and to modulate resistance to breast cancer endocrine therapy in vitro. We measured prognostic roles of circulating levels of seven major oxysterols in the
Louise Ménégaut et al.
Cell reports, 31(7), 107665-107665 (2020-05-21)
Low-grade inflammation is constitutive of atherosclerosis, and anti-inflammatory therapy inhibiting interleukin-1β (IL-1β) reduces the rate of cardiovascular events. While cholesterol accumulation in atheroma plaque and macrophages is a major driver of the inflammatory process, the role of the LXR cholesterol
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.